Literature DB >> 21372118

Multiple sclerosis: BAFF and CXCL13 in cerebrospinal fluid.

Samia Ragheb1, Yanfeng Li, Kirk Simon, Stephen VanHaerents, Daniela Galimberti, Milena De Riz, Chiara Fenoglio, Elio Scarpini, Robert Lisak.   

Abstract

BACKGROUND: There is increasing evidence of B-cell involvement in the pathogenesis of multiple sclerosis (MS). B-cell activating factor (BAFF) has an essential role in B-cell homeostasis. The chemokine CXCL13 has an important role in the formation and maintenance of B-cell follicles.
OBJECTIVE: To measure BAFF and CXCL13 levels in the cerebrospinal fluid (CSF) of patients with MS compared to patients with other neurological diseases.
METHODS: Cytokine/chemokine levels were measured by an enzyme-linked immunosorbent assay (ELISA).
RESULTS: In MS patients, BAFF levels were highest in patients with secondary progressive disease, and were higher during relapse in patients with relapsing-remitting and secondary progressive disease. CXCL13 levels were also higher during relapse. There was a positive correlation between CXCL13 and the IgG index, and an inverse correlation between BAFF and the IgG index. The implications of this finding are discussed.
CONCLUSION: During relapse, we found various positive correlations between BAFF, CXCL13 and the cytokines IL-6 and IL-10. These findings show that molecules that are essential for B-cell recruitment, survival, maturation and function may be working in concert to affect B-cell homeostasis in MS and contribute to the pathophysiology of the disease.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21372118     DOI: 10.1177/1352458511398887

Source DB:  PubMed          Journal:  Mult Scler        ISSN: 1352-4585            Impact factor:   6.312


  36 in total

1.  Cerebrospinal fluid BAFF and APRIL levels in neuromyelitis optica and multiple sclerosis patients during relapse.

Authors:  Honghao Wang; Kai Wang; Xiaonan Zhong; Wei Qiu; Yongqiang Dai; Aimin Wu; Xueqiang Hu
Journal:  J Clin Immunol       Date:  2012-05-30       Impact factor: 8.317

Review 2.  Blood Biomarkers as Outcome Measures in Inflammatory Neurologic Diseases.

Authors:  Nabil K El Ayoubi; Samia J Khoury
Journal:  Neurotherapeutics       Date:  2017-01       Impact factor: 7.620

Review 3.  A comprehensive review on the role of chemokines in the pathogenesis of multiple sclerosis.

Authors:  Soudeh Ghafouri-Fard; Kasra Honarmand; Mohammad Taheri
Journal:  Metab Brain Dis       Date:  2021-01-06       Impact factor: 3.584

Review 4.  Stage-specific immune dysregulation in multiple sclerosis.

Authors:  Benjamin M Segal
Journal:  J Interferon Cytokine Res       Date:  2014-08       Impact factor: 2.607

5.  Clonal relationships of CSF B cells in treatment-naive multiple sclerosis patients.

Authors:  Erica L Eggers; Brady A Michel; Hao Wu; Sheng-Zhi Wang; Carolyn J Bevan; Aya Abounasr; Natalie S Pierson; Antje Bischof; Max Kazer; Elizabeth Leitner; Ariele L Greenfield; Stanislas Demuth; Michael R Wilson; Roland G Henry; Bruce Ac Cree; Stephen L Hauser; H-Christian von Büdingen
Journal:  JCI Insight       Date:  2017-11-16

6.  Pearls & Oy-sters: CNS lymphoma in a patient with relapsing-remitting multiple sclerosis treated with interferon.

Authors:  Sharon Chiang; Navin K Kesari; Anthony Bradshaw; Wendy Chen; Rohini Samudralwar; Ammar M Alobaidy; Joseph S Kass
Journal:  Neurology       Date:  2017-10-24       Impact factor: 9.910

Review 7.  Exploring potential mechanisms of action of natalizumab in secondary progressive multiple sclerosis.

Authors:  Finn Sellebjerg; Diego Cadavid; Deborah Steiner; Luisa Maria Villar; Richard Reynolds; Daniel Mikol
Journal:  Ther Adv Neurol Disord       Date:  2016-01       Impact factor: 6.570

8.  Targeting CXCL13 During Neuroinflammation.

Authors:  Amanda K Huber; David N Irani
Journal:  Adv Neuroimmune Biol       Date:  2015-11-13

9.  Experimental laboratory biomarkers in multiple sclerosis.

Authors:  Borros Arneth; Jörg Kraus
Journal:  Wien Med Wochenschr       Date:  2022-03-07

Review 10.  Interleukin-10 paradox: A potent immunoregulatory cytokine that has been difficult to harness for immunotherapy.

Authors:  Ankit Saxena; Sam Khosraviani; Sanjeev Noel; Divya Mohan; Thomas Donner; Abdel Rahim A Hamad
Journal:  Cytokine       Date:  2014-12-04       Impact factor: 3.861

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.